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The Vaccinia virus gene, E3L, encodes a double-stranded RNA [dsRNA]-binding protein. We hypothesized that, owing to the critical nature of
dsRNA in triggering host innate antiviral responses, E3L-specific small-interfering RNAs [siRNAs] should be effective antiviral agents against
pox viruses, for which Vaccinia virus is an appropriate surrogate. In this study, we have utilized two human cell types, namely, HeLa and 293T,
one which responds to interferon [IFN]-β and the other produces and responds to IFN-β, respectively. The antiviral effects were equally robust in
HeLa and 293T cells. However, in the case of 293T cells, several distinct features were observed, when IFN-β is activated in these cells. Vaccinia
virus replication was inhibited by 97% and 98% as compared to control infection in HeLa and 293T cells transfected with E3L-specific siRNAs,
respectively. These studies demonstrate the utility of E3L-specific siRNAs as potent antiviral agents for small pox and related pox viruses.
© 2006 Elsevier Inc. All rights reserved.Keywords: RNAi; siRNA; Vaccinia; E3L; Innate immunityIntroduction
There has been a recent dramatic increase in interest in the
study of Smallpox and related pox viruses using modern
molecular virology tools. Recent incidences of monkey pox
virus infection of humans in the USA suggest its potential as an
emergent epidemiological agent. As well, the current geopolit-
ical scenario has implicated the use of Smallpox virus as a
potential bio-weapon. Smallpox was eradicated before the
emergence of recombinant DNA technologies and has therefore
not been fully studied with contemporary methods. Smallpox
pathogenesis is not understood adequately enough to suggest
detailed molecular mechanisms which are responsible for the
high death rate associated with the disease (Esposito andAbbreviations: IFN, Interferon; RNAi, RNA interference; siRNA, small
interfering RNA; dsRNA, double-stranded RNA; β-gal, β-galactosidase; PKR,
dsRNA-dependent Protein Kinase C.
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doi:10.1016/j.virol.2006.01.013Fenner, 2000). Vaccinations against Smallpox are complicated,
and substantial morbidity is associated with existing vaccines
(Moss, 2001). This is even further complicated by the presence
of a significant immunocompromised human population.
Exploring the role of siRNAs as effective antiviral agents
against pox viruses therefore merits consideration.
Vaccinia virus is an appropriate surrogate for studying
Smallpox viral pathogenesis. It is a relatively safe virus as it
does not cause serious disease in most immunocompetent
humans or animals (Diven, 2000). The genomes of both viruses
share substantial similarity, and many of the critical genes are
strongly conserved in the two viruses. For example, E3L,
encoding a dsRNA binding protein possesses an identical DNA
sequence in the Vaccinia and Variola genomes.
Immediately after viral infection, critical host defenses,
comprising the innate immune response, are induced. Innate
immune response makes a critical contribution to the activation
of adaptive immunity. However, there is a delay of 4 to 7 days
before the initial adaptive immune response takes place. Hence,
the innate immune response plays a critical role in initial viral
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subvert the innate immune response by secreting proteins that
inactivate complement (Kotwal et al., 1990), inhibit the IFN
response (Beattie et al., 1995; Carroll et al., 1993; Colamonici et
al., 1995; Symons et al., 1995), buffer against the inflammatory
response (Alcami et al., 1998) and prevent activation of natural
killer cells (Alcami and Smith, 1995). These proteins are likely
responsible for potent and often lethal infections associated with
the Smallpox virus (Diven, 2000). The proteins involved in
inhibiting the IFN response and preventing the activation of
natural killer cells include E3L (Chang et al., 1992), B18R
(Colamonici et al., 1995), K3L (Carroll et al., 1993) and B8R
(Alcami and Smith, 1995).
The Vaccinia E3L gene encodes a 25 kDa polypeptide
synthesized early during the viral life-cycle (Chang et al., 1992).
E3L is a dsRNA binding protein encoded by Vaccinia virus to
bypass the effects of IFNs. E3L is also anti-apoptotic and
oncogenic (Garcia et al., 2002). The critical role of E3L has
been demonstrated in several studies (Brandt et al., 2005;
Langland and Jacobs, 2002, 2004; Liu et al., 2001; Ludwig et
al., 2005; Xiang et al., 2002). B18R encodes a soluble IFN-α/β
receptor (Colamonici et al., 1995). B18R has sequence
similarities with type I IFN receptors and thus binds IFN-α/β
with high affinity. However, B18R is less species-specific than
the type I IFN receptors, enabling it to bind type I IFNs of
several species (Colamonici et al., 1995; Symons et al., 1995).
K3L encodes a homolog of the eukaryotic translation initiation
factor eIF-2α. K3L competitively inhibits phosphorylation of
eIF-2α (Carroll et al., 1993; Davies et al., 1993). B8R encodes a
soluble IFN-γ receptor that binds and antagonizes IFN-γ
(Alcami and Smith, 1995). Thus, it appears that E3L is the
critical gene that initiates the cascade that diminishes the
effectiveness of the innate immune response (Fig. 1).
The ability of E3L to function as a dsRNA binding protein
ensures that dsRNA is sequestered and RNAi is suppressed (Li
et al., 2004). dsRNA induces a multifaceted response in higher
eukaryotes, even when a single molecule is present (Cullen,Fig. 1. Molecular pathways by which Vaccinia subverts host defense mechanisms.
dsRNA, by producing the dsRNA binding protein E3L. Other key viral genes that are
immune response are B18R, B8R and K3L (see text for details and references).2002; Marcus and Sekellick, 1977). DNA viruses, such as
Vaccinia, generate dsRNA as a result of overlapping convergent
transcription. Late transcripts of Vaccinia are long and
heterogeneous. The early termination signal, TTTTTNT, is
not recognized by the late transcription system. Terminal
heterogeneity combined with transcription from both DNA
strands explains the ability of late transcripts to self-anneal or
anneal with early transcripts to form ribonuclease resistant
hybrids in vitro (Moss, 1996). dsRNA is an important pathogen-
associated molecular pattern that might provide enhanced
stimulation of innate immunity (Whitmore et al., 2004).
dsRNA binding proteins, encoded by several non-vertebrate
RNA viruses and vertebrate viruses, play a role in suppressing
RNAi (Dasgupta et al., 1998; Denzler and Jacobs, 1994;
Kaufman, 1999; Lichner et al., 2003). In mammalian cells,
RNAi functions independently of the IFN-induced pathways
(Brummelkamp et al., 2002; Cullen, 2002; Dave and Pomer-
antz, 2003; Sui et al., 2002; Yu et al., 2002). Thus, an siRNA-
based approach targeting E3L is likely to inhibit the virus by
triggering RNAi, as well as lead to an enhancement of the innate
immune response. Furthermore, an siRNA-based strategy that
enables destruction of the entire transcript will probably prevent
any of the diverse functions of E3L to be executed by its discrete
domains [such as nuclear localization, Z-DNA-binding,
dsRNA-dependent Protein Kinase C [PKR] binding and
dsRNA binding] (Brandt and Jacobs, 2001). Simultaneously
targeting E3L and B18R could possibly lead to a cumulative
enhancement of the antiviral effects by allowing the antiviral
effects of IFNs to be manifested. In the present study, we have
utilized E3L and B18R as targets for siRNAs in two cell types,
HeLa and 293T. HeLa cells were utilized for this study because
E3L deletions render the virus incapable of replication in this
cell type (Chang et al., 1995). As well, 293T cells were utilized
since they are able to both produce and respond to IFNs, while
HeLa cells are able to respond but not produce IFNs. The
present study enables us to determine whether these siRNAs can
be used as antiviral tools.Vaccinia virus masks the well-known pathogen-associated molecular pattern,
believed to play a role in preventing the generation of antiviral state and an innate
Fig. 3. E3L-specific siRNAs inhibit virion production in HeLa cells infected
with Vaccinia virus. HeLa cells were transfected with E3L-specific siRNAs,
along with scrambled control siRNAs. siRNAs were multiplexed, and four
different siRNAs were used for E3L. Cells were infected at the end of
transfection with Vaccinia virus at an MOI of 1.0 pfu/cell. The intracellular
mature virion concentration within HeLa cells was estimated by plaque titration
on B-S-C-1 cells at 2 dpi. The means of three experiments and standard
deviations are indicated.
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E3L-specific siRNAs inhibit Vaccinia virus replication and
production of progeny virions
To test whether the E3L- and B18R-specific siRNAs exert
antiviral effects, HeLa cells were transfected with these
moieties. The transfected cells were then infected with Vaccinia
virus at MOIs of 0.1 or 1.0 pfu/cell. The antiviral effect was
assayed at 2 dpi since it is known from our previous results that,
in similar systems, maximal antiviral effect is exerted at 2 dpi
(Dave and Pomerantz, 2004). The inhibition of viral replication
was assessed by measuring the β-gal enzyme activity in cell
extracts at 2 dpi. A plaque assay was used to assess the
inhibition of progeny virion production at 2 dpi. The plaque
assay measures the levels of intracellular mature virions.
At an MOI = 0.1 pfu/cell, E3L-specific siRNAs inhibited
viral replication to below detection levels [data not shown].
However, at an MOI = 1.0 pfu/cell, the E3L-specific siRNAs
inhibited viral replication to 7.6% of control infection
[P = 0.009] (Fig. 2). At neither of these MOIs were the
B18R-specific siRNAs able to inhibit viral replication
[P = 0.314 at MOI = 0.1 pfu/cell; P = 0.966 at MOI = 1.0
pfu/cell]. When E3L- and B18R-specific siRNAs were trans-
fected simultaneously, viral replication was inhibited to below
detection levels and 4.9% of control infection at MOI = 0.1 pfu/
cell and 1.0 pfu/cell respectively. The antiviral effect of E3L-
specific siRNAs was reflected similarly on the production of
infectious progeny virions. At an MOI = 1.0 pfu/cell, the E3L-
specific siRNAs inhibited the production of progeny virions to
4.5% of control infection [P = 0.009] (Fig. 3). We therefore
concluded that E3L-specific siRNAs have the ability to potently
inhibit Vaccinia virus replication and production of progeny
virions in HeLa cells. B18R-specific siRNAs failed to do so.Fig. 2. E3L-specific siRNAs inhibit viral replication in HeLa cells infected with
Vaccinia virus. HeLa cells were transfected with E3L- and B18R-specific
siRNAs, along with scrambled control siRNAs. siRNAs were multiplexed, and
four different siRNAs were used for each gene. Cells were infected at the end of
transfection with Vaccinia virus at an MOI of 1.0 pfu/cell. β-gal activity was
measured in cell extracts at 2 dpi. The means of three experiments and standard
deviations are indicated.As E3L-specific siRNAs had a consistent antiviral effect, we
therefore decided to individually evaluate the antiviral effects of
each of the four E3L-specific siRNAs that were multiplexed in
previous experiments. HeLa cells were transfected with
individual siRNAs, along with a scrambled control, and at the
end of transfection, infected with Vaccinia virus at an MOI = 1.0
pfu/cell. β-gal activity was measured in cell extracts at 2 dpi
(Fig. 4). E3L-C siRNA exerted the strongest and consistently
robust antiviral effect, inhibiting viral replication to 3.5% of
control infection [P = 0.003]. E3L-A and E3L-B siRNAs
inhibited viral replication to 17.2% and 64.3% of control,
respectively [P = 0.000003 and 0.008]. E3L-D siRNA failed to
inhibit viral replication. Since E3L-C siRNA was the most
potent of the four E3L-specific siRNAs tested, it was used in all
subsequent experiments to target E3L.
To evaluate the efficacy of E3L-C siRNA, the siRNAs were
transfected into HeLa cells and at the end of transfection
infected with Vaccinia virus at different MOIs ranging from 0.1
to 4.0 pfu/cell. E3L-C siRNAs inhibited viral replication in the
range of 14.6 to 23.85% of control infection (Fig. 5). Maximum
inhibitory effect was observed at MOIs ranging from 1.0 to 4.0
pfu/cell. At MOIs greater than 2 pfu/cell, HeLa cells that were
not transfected with E3L-C siRNAs exhibited cytopathic
effects. Increasing MOI from 2 pfu/cell to 4 pfu/cell did not
proportionately increase viral replication in control infections.
These results suggest that E3L-C siRNA is an efficient antiviral
moiety and has substantial efficacy, even at very high MOIs that
otherwise generate cytopathic effects in infected HeLa cells.
Having established the antiviral nature of E3L-specific
siRNAs in HeLa cells, we next tested them in 293T cells.
Cells were transfected with E3L-C siRNA and B18R-specific
siRNAs and at the end of transfection infected with Vaccinia
virus [MOI = 1.0 pfu/cell]. β-gal activity was measured in cell
extracts at 2 dpi (Fig. 6). Cells transfected with E3L-C siRNAs
exhibited a strong anti-proliferative effect, a likely consequence
of IFN-β activation [data not shown]. To ensure that infected
Fig. 4. E3L-C siRNAs were most efficient in inhibiting viral replication in HeLa cells infected with Vaccinia virus. HeLa cells were transfected with E3L-specific
siRNAs along with scrambled control siRNAs. Antiviral efficacy of each of the four E3L-specific siRNAs was determined. Cells were infected at the end of
transfection with Vaccinia virus at an MOI of 1.0 pfu/cell. β-gal activity was measured in cell extracts at 2 dpi. The means of three experiments and standard deviations
are indicated.
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being measured in uninfected cells, we assayed both the cell
extracts as well as culture supernatants. No β-gal activity was
detected in any of the culture supernatants. As in HeLa cells,
B18R-specific siRNAs failed to exert an antiviral effect in 293T
cells. E3L-C siRNA inhibited viral replication to 2.54%
[P = 0.0004] and 2.84% [P = 0.0004] of control infection,
alone or in combination with B18R-specific siRNAs respec-
tively. Thus, E3L-C siRNAs exert a potent antiviral effect in
HeLa and 293T cells.
E3L-specific siRNAs down-regulate E3L and B18R transcripts
We next performed semi-quantitative analyses to verify
changes in transcript levels of key viral genes, E3L, B18R, K3L
and B8R. Messenger RNA levels were measured in total RNA
samples isolated from HeLa and 293T cells transfected with E3L-Fig. 5. E3L-C siRNAs efficaciously inhibit viral replication at varying levels of
input virus in HeLa cells infected with Vaccinia virus. HeLa cells were
transfected with E3L-C siRNAs and then infected at varying MOIs with the
Vaccinia virus. β-gal activity was measured in cell extracts at 2 dpi. Control
represents HeLa cells infected with the virus alone. The means of three
experiments and standard deviations are indicated for E3L-C siRNA. For control
and scrambled siRNA, the experiment was performed with one replicate.C siRNAs and B18R-specific siRNAs and at the end of
transfection infected with Vaccinia virus [MOI = 1.0 pfu/cell].
Total RNA was extracted at 2 dpi. E3L-C siRNAs were able to
down-regulate E3L transcripts in HeLa and 293T cells (Fig. 7). A
reduction in E3L transcripts paralleled a reduction in B18R
transcripts. B18R-specific siRNAs did not seem to influence B18R
transcripts nor did they exert any antiviral effect in either cell type
tested. However, E3L-C siRNA possessed the ability to down-
regulate E3L and B18R transcripts. Of note, E3L-C siRNA do not
possess any sequence homology to B18R sequence.
Antiviral state generated by E3L-specific siRNAs involves
distinct features in HeLa and 293T cells
K3L and B8R appear to be differentially regulated in HeLa
and 293T cells transfected with E3L-specific siRNAs. InFig. 6. E3L-C siRNAs inhibit viral replication in 293T cells infected with
Vaccinia virus. 293T cells were transfected with E3L-C and B18R-specific
siRNAs along with scrambled control siRNAs. E3L-C siRNAwas used for E3L.
Four different siRNAs were used for B18R. Cells were infected at the end of
transfection with Vaccinia virus at an MOI of 1.0 pfu/cell. β-gal activity was
measured in cell extracts and culture supernatants at 2 dpi. The means of three
experiments and the standard deviations are indicated.
Fig. 7. Vaccinia virus genes involved in subverting the host defense mechanism
behave differently in HeLa and 293Tcells. HeLa and 293Tcells were transfected
with E3L- and B18R-specific siRNAs along with scrambled control siRNAs.
The siRNAs were multiplexed, and four different siRNA were used for B18R.
E3L-C siRNAwas utilized for E3L. Cells were infected at the end of transfection
with Vaccinia virus at an MOI of 1.0 pfu/cell. Total RNAwas isolated at 2 dpi.
Lane 1: 1 kbp ladder [Invitrogen], lane 2: uninfected HeLa or 293T cells, lane 3:
cells infected with Vaccinia virus, lane 4: cells infected with Vaccinia virus and
transfected with scrambled control siRNAs, lane 5: Cells infected with Vaccinia
virus and transfected with E3L-C siRNAs, lane 6: cells infected with Vaccinia
virus and transfected with B18R-specific siRNAs, lane 7: cells infected with
Vaccinia virus and transfected with E3L-C siRNAs along with B18R-specific
siRNAs. The numbers on the right side of each panel are the density ratio of the
RT-PCR products with reference to the sample from cells infected with Vaccinia
virus [lane 5 versus lane 3].
Fig. 9. IFN-β transcription is induced as a result of infection with Vaccinia virus
in 293T cells. HeLa [A] and 293T [B] cells were transfected with E3L- and
B18R-specific siRNAs, along with scrambled control siRNAs. The siRNAs
were multiplexed, four different siRNAwere used for B18R. E3L-C siRNAwas
used for E3L. Cells were infected after transfection with Vaccinia virus at an
MOI of 1.0 pfu/cell. Total RNAwas isolated at 2 dpi. Both panels show two sets
of lanes 1 to 7. In set 1, IFN-α transcripts were detected, and IFN-β transcripts
were detected in set 2. Lane 1: 1 kbp ladder [Invitrogen], lane 2: uninfected
HeLa or 293T cells, lane 3: cells infected with Vaccinia virus, lane 4: cells
infected with Vaccinia virus and transfected with scrambled control siRNAs,
lane 5: cells infected with Vaccinia virus and transfected with E3L-C siRNAs,
lane 6: cells infected with Vaccinia virus and transfected with B18R-specific
siRNAs, lane 7: cells infected with Vaccinia virus and transfected with E3L-C
siRNAs along with B18R-specific siRNAs.
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influenced by transcriptional down-regulation of E3L. How-
ever, in 293T cells, both gene transcripts were depressedFig. 8. E3L-specific siRNAs lead to greater inhibition of PKR activation in 293T
cells as compared to HeLa cells. HeLa and 293T cells were transfected with
E3L- and B18R-specific siRNAs along with scrambled control siRNAs. The
siRNAs were multiplexed, and four different siRNAwere used for B18R. E3L-C
siRNA was used for E3L. Cells were infected at the end of transfection with
Vaccinia virus at an MOI of 1.0 pfu/cell. PKR activity was measured in cell
extracts from HeLa cells [A] and 293T cells [B]. Lane 1: uninfected HeLa or
293T cells, lane 2: cells infected with Vaccinia virus, lane 3: cells infected with
Vaccinia virus and transfected with scrambled control siRNAs, lane 4: cells
infected with Vaccinia virus and transfected with E3L-C siRNAs, lane 5: cells
infected with Vaccinia virus and transfected with B18R-specific siRNAs, lane 6:
cells infected with Vaccinia virus and transfected with E3L-C siRNAs along
with B18R-specific siRNAs. The numbers under each panel are the density ratio
of the fluorescent phosphorylated peptide bands with reference to the sample
from cells infected with Vaccinia virus.when E3L transcripts were down-regulated. Transcriptional
down-regulation of K3L and B8R, along with that of E3L and
B18R, occurred only in 293T cells by E3L-C siRNA (Fig. 7).
To gain further initial insights into the molecular mechanism
[s] that might be associated with the emergence of antiviral state
upon transfection with E3L-C siRNAs, we investigated PKR
activation and IFN-α/β expression at 2 dpi in HeLa and 293T
cells infected with Vaccinia virus [MOI = 1.0 pfu/cell]. In HeLa
cells, PKR was not activated post-infection, irrespective of the
fact that cells were transfected with any siRNAs. There was
slight PKR inhibition in HeLa cells transfected with E3L-C
siRNAs. However, in 293T cells, PKR activation was inhibited
to 45% in cells transfected with E3L-C siRNAs as compared to
cells infected with Vaccinia virus only (Fig. 8). As well, in HeLa
cells, IFN-α/β transcripts were constitutively expressed.
However, in 293T cells, only IFN-α transcript expression was
constitutive. IFN-β transcripts were expressed only in cells that
were infected with the Vaccinia virus (Fig. 9). Hence, E3L-C
siRNAs were able to generate an antiviral state in both cell
types. However, inhibition of PKR activity and transcriptional
down-regulation of K3L and B8R occurred only in 293T cells.
The distinct features associated with generation of antiviral state
in 293T cells might be attributed to the differential expression of
IFN-β in this cell type.
Discussion
These data demonstrate that E3L-C siRNAs are effective in
inhibiting Vaccinia virus infection. E3L encodes a dsRNA
binding protein. Transcriptional down-regulation of this protein
is likely to unmask the dsRNA. While HeLa cells are able to
respond to IFN-β, they do not produce this moiety. On the other
hand, 293T cells respond, as well as produce, IFN-β. That
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293T cells possessed distinct features not observed in HeLa
cells suggests that IFN-β plays a role in the generation of an
antiviral state.
Down-regulation of E3L transcripts led to down-regulation
of B18R, K3L and B8R transcripts. While cells transfected with
E3L-C siRNA and infected with Vaccinia virus show down-
regulation of E3L and B18R transcripts, however, that was not
the case in cells transfected with B18R-specific siRNAs. The
inability of B18R-specific siRNAs to inhibit viral replication is
surprising. Since B18R binds to type I IFNs, the effect of
targeting E3L and B18R should have been cumulative
(Colamonici et al., 1995). The gene is perhaps not likely
critical in controlling viral replication in the two cell types
which were analyzed. No transcriptional down-regulation of
B18R was observed. This could be because the gene is
dispensable. Even when the siRNAs attempt to down-regulate
the transcripts, the virus continues to grow and the transcript
levels parallel viral replication. That all four of the B18R-
specific siRNAs were ineffective is very unlikely, though it
cannot be unequivocally ruled out. Although E3L binds
dsRNA, it is unlikely that E3L binds to 21-bp siRNAs. In that
case, the E3L-specific as well as B18R-specific siRNAs would
not be able to exert antiviral effects. Clearly, that is not the case
as E3L-specific siRNAs were effective. E3L-mediated inhibi-
tion of RNAi might be a possible explanation. We have
observed that siRNA-mediated down-regulation of GAPDH is
ineffective in the context of Vaccinia viral infection. In such a
scenario, siRNA-mediated antiviral strategy targeting E3L
might be the most effective approach. The ability of E3L-C
siRNAs to target B18R and E3L transcripts suggests that it is an
excellent antiviral moiety.
Unlike B18R, concomitant decrease of K3L and B8R
transcripts appears to be dependent on the IFN producer
phenotype of the cells. It is likely that IFN-β plays a pivotal role
in enabling E3L to regulate transcription of both the genes.
Several studies have demonstrated molecular interactions
between the gene products of E3L and K3L (Davies et al.,
1993; Langland and Jacobs, 2002). However, thus far, the
ability of E3L to regulate transcription of K3L and B8R has not
been demonstrated.
Our results demonstrate that response of PKR is dependent
on the IFN producer phenotype of the cells. Similar observation
was made in a study that utilized ΔE3L and ΔK3L Vaccinia
viruses in HeLa and BHK cell types (Langland and Jacobs,
2002). Vaccinia virus carrying a deletion for E3L has been
known to activate PKR in IFN-treated Cos-1 cells (Chang et al.,
1992). However, we have not observed PKR activation in
situations where E3L is possibly down-regulated [by E3L-
specific siRNAs] in either cell type tested. Of note, E3L-specific
siRNAs inhibited PKR in 293T cells. In HeLa cells, no
significant changes in PKR activation were observed. Most of
the studies with mutant viruses have treated cells with IFN
(Chang et al., 1992; Langland and Jacobs, 2002). We have
observed that, if 293T cells were treated with a substantial
amount of poly[I][C] [100 μg/mL], a small quantity of IFN-β
was detected by ELISA and PKR was activated [data notshown]. HeLa cells did not produce IFN-β, although transcripts
for IFN-β were detected.
The inhibition of PKR as well as transcriptional down-
regulation of K3L and B8R was observed only in 293T cells
transfected with E3L-C siRNAs. While connection between
B8R and PKR is unknown, a close relationship between K3L
and PKR exists. K3L is a competitive inhibitor of and acts as a
pseudo-substrate of PKR. As such, observations about the
relationship between K3L and PKR are cell-dependent. In HeLa
cells, K3L is not essential for viral replication, however, in
BHK-1 cells, it plays a critical role paralleling E3L (Chang et
al., 1992). The activation curve for dsRNA is bimodal, where
low concentrations of dsRNA activate and high concentrations
of dsRNA inhibit activation of PKR (Kaufman, 2002). The
amount of dsRNA un-sequestered upon transcriptional down-
regulation of E3L in the two cell types might be different and is
the likely reason for distinct PKR activation profiles.
Taken together, our results suggest that siRNAs targeting
E3L are effective in potently inhibiting Vaccinia virus. Thus
far, siRNA-based antiviral approaches against Vaccinia virus
and related poxviruses have not been described. The antiviral
effects of E3L-specific siRNAs probably involved down-
regulation of the protein as well. However, this has not been
unequivocally established in this study. E3L very likely plays
the initiating role in evading the initial innate immune
response. As such, this approach has a strong potential of
enhancing the innate immune response and thereby preventing
a potent Vaccinia viral infection. Recently, two studies have
described that presence of uridine-rich sequences, irrespective
of the GC content, exerts a potent immunostimulatory effect
through Toll receptors (Hornung et al., 2005; Judge et al.,
2005). Neither motifs, 5′-UGUGU-3′ and 5′-GUCCUUCAA-
3′, are present on the sense strand of any of the siRNA
sequences that we have tested in the present studies. Thus,
enhancement of innate immune response will be a direct
consequence of the down-regulation of dsRNA binding
protein E3L. The motif 5′-UGUGU-3′ occurs 149 times in
the Vaccinia WR genome. The other uridine-rich sequence
does not occur at all. As late stages of Vaccinia infection
generates dsRNA, the 5′-UGUGU-3′ motif is likely to be
incorporated. When dsRNA is un-sequestered, the resultant
siRNA generated have the possibility of possessing the
immunostimulatory motif, thereby further enhancing the
innate immune response in a specific manner.
These studies demonstrate that, indeed, siRNA-based anti-
virals are potent and effective approaches against a poxvirus. As
well, targeting the mechanisms by which poxviruses subvert the
host's innate immune system will not only likely yield novel
therapeutics but can functionally interrogate the complex viral:
innate immune system interactions.
Materials and methods
Cells and viral stocks
HeLa, 293T and B-S-C-1 cells [ATCC] were maintained in
Dulbecco's modified Eagle Medium containing 10% heat-
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mL penicillin G and 50 μg/mL streptomycin. Recombinant
Vaccinia virus [VSC-56] expressing the β-galactosidase [β-gal]
gene at the thymidine kinase locus was used in all experiments.
β-gal expression was under the control of the natural p7.5 early/
late promoter element (Bronte et al., 1997). Viral stocks were
prepared in HeLa cells, as described previously (Earl and Moss,
1991). Viral concentrations were determined by plaque titration
on B-S-C-1 cells.
siRNA selection, preparation and transfection
Web-based tools from Ambion, Whitehead Institute for
Biomedical Research, Massachusetts Institute of Technology
and the National Center for Biotechnology Information
websites were used for selection of siRNA sequences and for
Blast searches. siRNA sequences were Blast-searched either in
the EST-Human database or databases containing viral nucleic
acid sequences. In either case, Blast searches were for “short
nearly exact matches”. Chemically synthesized siRNAs were
utilized in all the experiments [Dharmacon]. The siRNA
duplexes with 3′-AA overhangs were duplexed, desalted,
purified and 2′-deprotected. siRNA duplexes [20 μM] were
stored in 6 mM HEPES-KOH buffer, pH 7.5 containing 20 mM
KCl and 0.2 mM MgCl2 at −20 °C. Scrambled [negative
control] siRNAs [Ambion] were used to ensure the specificity
and statistical significance of the observed antiviral effects.
Statistical significance of the antiviral effects was determined
with reference to samples from cells infected with Vaccinia.
However, during the course of the study, we determined the
specificity and statistical significance of antiviral effects with
reference to samples from cells infected with Vaccinia as well as
cells transfected with Scrambled control siRNA and then
infected with Vaccinia.
The siRNA sequences used to down-regulate E3L were E3L-
A [5′-AAU ACU CUC CCG UCG AUG UCU-3′], E3L-B [5′-
AAG ACU UAU GAU CCU CUC UCA-3′], E3L-C [5′-AAU
AUC GUC GGA GCU GUA CAC-3′] and E3L-D [5′-AAC
GCU CGU CAA UAU AGA UCU-3′]. The following four
sequences were used to down-regulate B18R; B18R-A [5′-AAA
GUG UCC UCC UAU UGA AGA-3′], B18R-B [5′-AAC CUG
CCA AUA UAA CAU GCA-3′], B18R-C [5′-AAU CCA UCC
GGA UGG CUU AUA-3′] and B18R-D [5′-AAA UGU CGU
GGA CAC AAC UAU-3′]. siRNAs were transfected, as
described previously (Dave and Pomerantz, 2004). For HeLa
cells, siPort Lipid [Ambion] was used to transfect siRNA.
Lipofectamine 2000 [Invitrogen] was used to transfect 293T
cells. All transfections were in 6-well plates, 6 × 104 cells were
plated in each well in DMEM containing 10% heat-inactivated
FBS and 2 mM L-glutamine. Approximately 18 h after plating,
when the cells had reached 30% confluence, siRNA [10 pmol/
well] siPort lipid [Ambion] or Lipofectamine [Invitrogen]
complexes in Optimem-I were added for transfection for 5 h.
Lipid complexes were generated according to manufacturer's
instructions. At the end of the 5-h transfection, cells were
infected with the recombinant Vaccinia virus [MOI; 0.1 or 1.0
pg p24/cell] for 2 h. At the end of the 2-h period, cells werewashed with phosphate-buffered saline [PBS] to remove input
virus. Cells were cultured in Optimem-I medium without any
supplements for 2 days. Viral replication was assessed by
measuring β-gal activity in cell extracts, and production of
progeny virions was assessed by measuring the quantity of
intracellular mature virions at 2 days post-infection [dpi].
β-gal enzyme assay
The β-gal enzyme assay kit [Promega] was used to measure
the activity of the enzyme in cell extracts from HeLa or 293T
cells, essentially according to manufacturer's instructions with a
few modifications. Adherent cells were harvested with trypsin.
Cells were washed with chilled PBS containing 5% FBS
followed by another wash with PBS. Cells [6 × 104] were
finally extracted in 150 μL of 1× Reporter Lysis Buffer
provided in this kit. The assay measures the ability of β-gal to
hydrolyze ο-nitrophenyl-β-D-galactopyranoside [colorless] to
ο-nitrophenyl [yellow]. The assay is expected to maintain a
linear range with respect to standards, if it is performed for 30
min. That is not typically the case with test samples, and the
reaction is terminated to ensure that the values can be
interpolated from the standard curve. Hence, values are
typically compared within a particular experimental set and
not across different sets of experiments.
PKR activation assay
A PepTag® Non-Radioactive PKR assay kit [Promega]
was used to determine PKR activation according to
manufacturer's instructions with a few modifications. Cells
were harvested as described above for the β-gal enzyme assay
and extracted in 200 μL chilled buffer, 25 mM Tris–HCl, pH
7.4, containing 0.5 mM EDTA, 0.5 mM EGTA, 0.05%
TritonX-100, 10 mM β-mercaptoethanol, 1 μg/mL Leupeptin,
1 μg/mL Aprotinin and 1 mM PMSF. 10% of the sample was
used in the assay, and the entire reaction mix [50 μL] was
analyzed by electrophoresis through a 0.8% agarose gel in 50
mM Tris–HCl, pH 8.0. The fluorescent peptides were
visualized by UV illumination. The gel photographs were
scanned and further analyzed for density comparison by using
IQ Mac v1.2 software [Molecular Dynamics]. The density
ratio of the fluorescent phosphorylated peptide bands in test
samples was determined with reference to the sample from
cells infected with Vaccinia virus.
Reverse transcriptase-polymerase chain reaction [RT-PCR]
Total RNA was extracted from HeLa and 293T cells
[transfected with siRNA and infected with Vaccinia] at 2 dpi
with RNeasy mini-kit [Qiagen]. RNA was incubated with
deoxyribonuclease I, amplification grade [Invitrogen] to
remove residual genomic DNA. Reverse transcription was
performed with SuperScript One-Step RT-PCR with Platinum
Taq kit [Invitrogen], and the reaction products were analyzed on
1.5% agarose gel. The following primer pairs were used;
GAPDH_77-96F [5′-GAG TCA ACG GAT TTG GTC GT-3′]
496 R.S. Dave et al. / Virology 348 (2006) 489–497and GAPDH_295-314R [5′-TTG ATT TTG GAG GGA TCT
CG-3′], E3L_396-415F [5′-CGG AGC TGT ACA CCA TAG
CA-3′] and E3L_540–559R [5′-TAT TGA CGA GCG TTC
TGA CG-3′], B18R_384-403F [5′-TGT GGT TAA ATG GGA
AAG GC-3′] and B18R_1055-1074R [5′GTA CAA GGT CGC
CTC GGTAA], K3L_145-168F [5′-TGC CAA GATAGC TTC
AAA GTG AGG-3′] and K3L_234-253R [5′-TTA TTC GTT
GCC CAATGC GG-3′], B8R_405-424F [5′-CAA ACG CGG
TGA CAT GTG TG-3′] and B8R_560-579R [5′-TTC TGT
GGC TCC CTG TGC TG-3′], IFNA_28-47F [5′-ACC CAT
CTC AGC AAG CCC AG-3′] and IFNA_550-569R [5′-TGA
CAA CCT CCC AGG CAC AA-3′], IFNB_202-221F [5′-TGG
CAA TTG AAT GGG AGG CT-3′] and IFNB_473–493R [5′-
TGC TCA TGA GTT TTC CCC TGG-3′]. The expected
product sizes were as follows, GAPDH [237 bp], E3L [163
bp], B18 R [690 bp], K3L [108 bp], B8R [174 bp], IFN-α [453
bp] and IFN-β [291 bp]. The gel photographs were scanned
and further analyzed for density comparison by using IQ Mac
v1.2 software [Molecular Dynamics]. The density ratio of the
RT-PCR products from total RNA obtained from cells
transfected with E3L-specific siRNAs was determined with
reference to the similar sample from cells infected with
Vaccinia virus.
Statistical analysis
Statistically significant differences between control and test
groups were determined by Student's t test. P values of ≤0.05
were considered significant. All the analyses were performed in
Microsoft Excel.
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